Two immunology stories landed on opposite sides of the same coin this week, and together they tell you how hard this business is even for the winners.
Argenx, the company that turned the FcRn mechanism into Vyvgart and one of the great recent commercial successes in autoimmune disease, is paying $2.2 billion for Forte Biosciences to get a Phase 2 drug for vitiligo and celiac disease. This is a company using the cash from its winner to buy its way out of single product risk, the same logic driving Vertex into endocrinology, Lilly into psychedelics, and the entire M&A wave that has defined this year.
Sanofi is living the other version of that story. The framing around its amlitelimab discontinuation hardened over the weekend into a $1.4 billion Kymab bet that has now faltered. The company said it will not seek approval for the OX40 ligand antibody in atopic dermatitis because the drug would not represent a meaningful improvement over the standard of care. That is a blunt admission about a drug that was supposed to be a Dupixent successor.
Argenx is buying its way into immunology’s future. Sanofi is watching a piece of its own future evaporate. Same sector, same week, opposite trajectories.
Section 232 tariffs hit large companies Friday. And AI generated data has become a genuine sticking point in biopharma dealmaking.
Argenx Is Buying Its Second Act
What Happened: Argenx agreed to acquire Forte Biosciences for $2.2 billion, gaining a Phase 2 stage drug for vitiligo and celiac disease.
The Single Product Company’s Most Important Decision
Argenx built itself on Vyvgart, its FcRn blocker that has become a major success across myasthenia gravis and other autoimmune conditions. The drug works by reducing the levels of harmful antibodies that drive autoimmune disease, and it has delivered the kind of commercial performance that turns a clinical stage biotech into a company with real scale, real infrastructure, and real cash flow.
But every successful single product company faces the same question: what comes next? Vyvgart is generating the revenue and the credibility that give argenx the resources to expand. The risk is that a company defined by one mechanism and one franchise is exposed—to competition, to patent timelines, and to the simple concentration of having everything depend on one thing going right. The best time to diversify is from a position of strength, which is exactly where argenx sits right now.
Why Vitiligo and Celiac Disease
The two diseases Forte brings are both large autoimmune markets with genuine unmet need.
Vitiligo is a visible, psychologically burdensome pigment loss condition where treatment options are limited. The disease causes patches of skin to lose their color, and for many patients the cosmetic and emotional impact is severe. Existing treatments are modest—topical JAK inhibitors (Incyte’s Opzelura) address limited areas but do not offer the systemic control that a significant proportion of patients need. A systemic drug that could restore pigmentation across the body would address a gap that millions of patients live with.
Celiac disease is one of the largest autoimmune conditions in the world with no approved drug therapy at all. The only current management is strict dietary avoidance of gluten, which is difficult to maintain perfectly and which leaves many patients with ongoing symptoms, nutritional deficiencies, and reduced quality of life even when they adhere to the diet. A drug that could allow celiac patients to tolerate gluten exposure without the immune mediated intestinal damage the disease causes would be genuinely transformative. The market is effectively greenfield—any approved therapy enters with no competition because no drug has been approved for the condition.
Both diseases fit argenx’s autoimmune expertise. The company has spent years understanding how the immune system attacks the body’s own tissues, how to intervene in that process, and how to build clinical programs and commercial infrastructure around autoimmune disease. Applying that expertise to new mechanisms and new diseases is the logical next step, and buying a mid stage asset rather than waiting on internal discovery lets argenx move faster.
The Risk Is Real But the Logic Is Sound
Phase 2 drugs fail in Phase 3 all the time. There is no guarantee that the Forte asset will deliver the clinical results needed for approval in either vitiligo or celiac disease. Argenx is paying $2.2 billion for a mid stage program, which means a significant portion of the deal’s value depends on clinical outcomes that have not yet been generated.
But argenx has the balance sheet to absorb a failure and try again. The GLP 1 franchise funds Lilly’s fifteen deal spree. Vyvgart funds argenx’s expansion in a similar way, at a different scale. If the Forte assets deliver, argenx becomes a multi product immunology company with three distinct disease franchises. If they fail, the Vyvgart cash flow continues, the company learns, and it makes the next acquisition with the benefit of that experience. This is what it looks like when a single product success tries to become a durable franchise—and argenx is making that attempt from a position of genuine strength.
Sanofi’s $1.4B Kymab Bet Faltered, and the Post Dupixent Plan Took a Hit
What Happened: The framing around Sanofi’s decision to drop amlitelimab hardened over the weekend. Sanofi said it will not seek approval of the OX40 ligand antibody in atopic dermatitis because it would not represent a meaningful improvement over the standard of care.
Why This Admission Hurts More Than a Typical Pipeline Cut
Amlitelimab came from Sanofi’s $1.4 billion acquisition of Kymab in 2021. The company positioned the drug as a future growth driver in immunology—specifically, as part of the pipeline that would carry the immunology franchise forward when Dupixent eventually faces its patent cliff. Dupixent generated $14 billion in 2025 revenue. It is the franchise that defines Sanofi’s growth story. And the drug that was supposed to help replace it just washed out of its lead indication.
Saying a drug “would not represent a meaningful improvement over the standard of care” is about as candid as pharmaceutical companies get about a discontinued program. It is not a safety issue that requires withdrawal. It is not a regulatory disagreement about endpoints. It is an acknowledgment that the drug, even if it worked, would not work well enough to matter in a market where Dupixent has set a high bar and AbbVie’s zumilokibart (two to four injections per year versus Dupixent’s 26) is positioning as the next generation challenger.
The Accumulation Is the Problem
We flagged Monday that the pressure on Sanofi is building. Stack up the year:
Riliprubart failed Phase 3 in CIDP, removing another pipeline asset from the growth plan.
The EU opened an antitrust investigation into whether Sanofi disparaged a rival flu vaccine, adding regulatory and reputational risk.
The FDA issued a warning letter at the Genzyme manufacturing site in Ireland over Altuviiio production violations, raising questions about manufacturing execution at a key facility.
And now amlitelimab is discontinued in its lead indication, the biggest pipeline setback because it hits the post Dupixent plan directly.
No single one of these events is fatal. Sanofi retains a strong commercial base, a real vaccines business, meaningful rare disease assets, and the Dupixent franchise is still generating enormous revenue. The company is not in crisis. But the pattern raises a genuine question: can Sanofi’s pipeline deliver the growth it needs before the Dupixent cliff arrives? Each setback narrows the margin for error and increases the weight on whatever remains in the pipeline. The company needs a clear, convincing win to reset the narrative, and it needs it soon.
Amlitelimab may yet have life in other indications beyond atopic dermatitis—the OX40 ligand mechanism could work in different autoimmune contexts where the competitive bar is lower. But the loss of the flagship indication, in the disease that Dupixent built, is the kind of setback that changes how the market evaluates the company’s forward trajectory.
AI Data Has Become a Dealmaking Battleground
What Happened: A BioSpace analysis found that where and how data gets generated has become a sticking point in partnerships between big pharma and AI biotechs.
The Shift from Hype to Hard Negotiation
For two years, the AI drug discovery story was about the promise and the headline partnerships. Isomorphic Labs signing with Lilly and Novartis. Insilico partnering with Takeda, SK Biopharmaceuticals ($2.5 billion), and Servier ($888 million). The Anthropic ecosystem spanning five of the top ten pharma companies. Chai Discovery raising $400 million at a $3.8 billion valuation. The deals made headlines. The details were secondary.
Now that these collaborations are generating actual value—real molecules being designed, real candidates being optimized, real experimental data being produced—the parties are fighting over the practical questions that determine who captures that value. Chief among them: who owns and controls the data?
In an AI drug discovery collaboration, value is created in two places. The models that generate hypotheses, identify targets, and design molecules. And the experimental data that trains, validates, and improves those models. The AI biotech typically brings the models. But the data comes from a mix of sources: the pharma partner’s proprietary datasets, the biotech’s own generated data, and new data produced during the collaboration itself. Who owns the data generated during the partnership, who can use it after the partnership ends, and who controls how it is shared determines who benefits from the collaboration not just now but for years to come.
These questions did not matter when the partnerships were aspirational. They matter enormously now that they are real. A pharma company that hands proprietary data into a collaboration wants assurance that the data will not end up improving a model that a competitor later accesses. An AI biotech that generates valuable data during a deal wants to retain the right to use it across its platform, because the data improves the model’s capabilities for all future partnerships, not just the current one.
The friction is a healthy sign. Companies fight over data ownership when the data is actually valuable, which means the partnerships are producing something worth arguing about. It is a step up from the era when the deals were mostly about signaling and optionality. But it is also a practical challenge that will shape how future AI drug discovery deals get structured. The companies with the most valuable proprietary data—not just the best models—hold real leverage, because high quality data is harder to replicate than a model architecture.
Section 232 Tariffs: Four Days Out
The Section 232 pharmaceutical tariffs take effect for large companies this Friday, July 31. Four days from today.
The tariffs have been on our calendar since the spring, and the industry has had months to prepare. But preparation and implementation are different things. Companies have announced onshoring investments (Lilly, Regeneron, Hikma, BeOne). They have modeled their tariff exposure. They have adjusted inventory positions for products manufactured overseas.
What they have not done, and cannot do in four days, is fundamentally change where their drugs are made. Manufacturing relocation takes years. New facilities require construction, regulatory approval (each manufacturing site needs FDA inspection and clearance), raw material qualification, and production scaling. The Section 232 tariffs are the starting gun for that process, not the finish line.
The tariffs arrive on top of the 2028 generic drug import tariffs Trump announced last week, framed explicitly as a penalty for companies that do not reshore production. Together they create a policy environment where both branded and generic imports face rising costs. For companies already navigating the MFN pricing framework, the Medicare Bridge copay structure, and European pricing reforms, the Section 232 tariffs add another layer to an already complex pricing and supply chain environment.
We will cover the tariff impact as it lands on Friday.
Quick Hits
New COVID vaccine patent lawsuits added to the growing web of legal disputes over the mRNA technology behind the pandemic shots. The IP fights that the COVID vaccines spawned—between Moderna, Pfizer/BioNTech, and the academic institutions that contributed foundational mRNA research—are far from settled. Each new lawsuit extends a legal landscape that will take years to resolve and that will ultimately determine who controls the mRNA platform for future vaccines beyond COVID.
Insmed strengthened its support for a closely watched pulmonary hypertension drug, reinforcing a program in one of the more competitive cardiopulmonary markets. The pulmonary hypertension treatment landscape has evolved rapidly, with multiple approved therapies and several new mechanisms in development. Insmed’s program adds to a growing field where patient outcomes are improving but where significant unmet need remains for patients who do not respond adequately to existing options.
Zevra Therapeutics plans to ask the EMA to approve Daybu (trofinetide) in Rett syndrome, following Acadia’s path and extending the reach of one of the few treatments for the rare neurodevelopmental disorder. Rett syndrome affects primarily girls and causes severe communication and motor impairments. Expanding geographic access for an approved therapy in a disease this underserved is meaningful for the small patient community.
Amgen laid off around 40 employees, a small cut that fits the slowing but not vanished layoff trend we have tracked. After Friday’s data showing layoffs would need to double in the second half to match 2025, individual restructurings continue even as the aggregate improves. Amgen is simultaneously navigating the Tavneos regulatory crisis (pivotal study retracted, CHMP revocation, FDA voluntary removal request), which adds a particular kind of organizational stress beyond routine headcount management.
Strategic Themes
1. Argenx Is Showing How a Successful Single Product Company Graduates to a Franchise
Use the cash from the winner to buy the next mechanism. Diversify from a position of strength rather than waiting until the pressure forces it. Target diseases with genuine unmet need where the company’s autoimmune expertise transfers. That is the playbook argenx is running with the Forte acquisition, and it is the same playbook Vertex used with Crinetics, Pharming, and its type 1 diabetes program. The companies that make this transition successfully become durable multi franchise businesses. The ones that do not become acquisition targets themselves.
2. Sanofi’s Post Dupixent Plan Has Lost Its Most Important Piece
Amlitelimab was not a minor pipeline asset. It was the designated successor in the disease that Dupixent built. Losing it in atopic dermatitis removes the most direct answer to the question that defines Sanofi’s next decade: what replaces $14 billion in annual Dupixent revenue when the patent cliff arrives? The remaining pipeline has to step up, and the margin for further disappointment is thin.
3. AI Drug Discovery Is Maturing from Headline Deals into Hard Negotiation
When companies fight over data ownership, the partnerships are real enough and valuable enough to be worth fighting over. That is a maturation from the era when AI drug discovery deals were about signaling and optionality. The shift from “who signs the biggest deal?” to “who controls the data?” is the practical evolution that separates genuine platform value from narrative. The AI biotechs that control unique, high quality datasets will hold the most leverage as these partnerships mature.
4. The Section 232 Countdown Is the Policy Story of the Week
Four days to the tariff deadline for large companies. The industry has prepared as much as it can in the timeframe available, but fundamental manufacturing shifts require years, not months. Friday is when the cost of importing pharmaceutical products rises, and the earnings calls over the next quarter will show how companies absorb, pass through, or adjust to that new cost reality.
Frequently Asked Questions
What is the argenx/Forte deal?
Argenx is acquiring Forte Biosciences for $2.2 billion, gaining a Phase 2 drug for vitiligo and celiac disease. The deal diversifies argenx beyond its Vyvgart FcRn franchise into new autoimmune diseases with significant unmet need. Celiac disease has no approved drug therapy at all.
What happened with Sanofi’s amlitelimab?
Sanofi said it will not seek approval for the OX40 ligand antibody in atopic dermatitis because it would not represent a meaningful improvement over the standard of care. The drug came from the $1.4B Kymab acquisition and was positioned as a Dupixent successor. Its loss in the lead indication is Sanofi’s most significant pipeline setback of the year.
What is the AI data issue?
Big pharma and AI biotechs are arguing over who owns and controls the data generated during drug discovery collaborations. The data trains and improves the AI models, making it valuable beyond any single partnership. Ownership and usage rights have become central negotiation points as these partnerships mature from aspirational to operational.
When do Section 232 tariffs hit?
Friday, July 31, for large companies. September 29 for all others. They arrive on top of the 2028 generic drug tariffs announced last week. Together they create rising costs on both branded and generic drug imports.
Is Amgen still laying off?
About 40 employees this week. It fits the trend of individual cuts continuing even as the sector wide wave has broken. Amgen is simultaneously navigating the Tavneos regulatory crisis.
What about COVID patent lawsuits?
New lawsuits added to the growing legal tangle over mRNA vaccine technology. The IP fights between Moderna, Pfizer/BioNTech, and academic institutions are far from resolved and will determine who controls the mRNA platform for future vaccines.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Argenx Is Buying Its Second Act. We analyze whether the Vyvgart playbook transfers to vitiligo and celiac disease, assess the clinical and commercial risk of a $2.2B bet on a Phase 2 asset, and evaluate how the deal positions argenx against the broader mid cap immunology landscape.
Sanofi’s Post Dupixent Plan Lost a Pillar. We compile what remains of the growth story after four setbacks this year, assess whether the pipeline can deliver the revenue replacement Sanofi needs before the Dupixent cliff arrives, and identify which remaining readouts carry the most weight.
AI Data Is the Real Asset. We explain why data ownership became the central negotiation in AI drug discovery deals, assess which AI biotechs hold the most leverage through proprietary datasets, and map how the data question reshapes the partnership structures going forward.
Plus: Section 232 tariff countdown (4 days), COVID mRNA patent landscape, Insmed pulmonary hypertension, Zevra Rett syndrome EMA path, Amgen layoffs in context, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
